Quick-Med Technologies Board of Directors

The Board oversees the conduct and supervises the management and affairs of the Company.

Board of Directors:
Michael R. Granito
J. Ladd Greeno
MG. George E. Friel (Ret.)
Gerald M. Olderman, Ph. D.
Gregory S. Schultz, Ph.D.

Biography:

Michael R. Granito
Chairman of the Board

Mr. Granito has served as chairman of the board since July 2000. In September 2003, Mr. Granito joined Federated Investors, Inc. as senior vice president and head of capital market research. From July 1979 to December 2002, Mr. Granito was the managing director and head of capital market research of J.P. Morgan Fleming Asset Investment Management. From 1984 through 1996 he served as an adjunct professor of finance at Yale University and New York University (NYU). Mr. Granito has authored a book and 14 pages on finance and foreign exchanges topics. In 1973, Mr. Granito earned a B.S. and a B.A. in Economics from the University of Pennsylvania.

J. Ladd Greeno
CEO

Mr. Greeno is CEO of Quick-Med Technologies and a member of the board of directors, positions to which he was named in late 2007. From 2003 to 2006, Mr. Greeno was President and CEO of Agion Technologies (Agion), a leading provider of ionic silver antimicrobials. Before joining Agion, Mr. Greeno held a number of senior management positions at the global management and technology consulting firm, Arthur D. Little, Inc. (ADL), including COO and senior vice president in charge of the firm’s north american management consulting business. Mr. Greeno began his consulting career in ADL’s Strategy & Organization practice and then moved into leadership roles successfully building ADL’s worldwide environment, health, and safety consulting business. Mr. Greeno received an M.B.A. from Harvard Business School and a B.B.A. from the University of Oklahoma.

George E. Friel
 

IMG. Friel has been self-employed as a consultant to various organizations in the defense industry since September 1998. MG. Friel served in the U.S. Army from 1960 to 1998. He was the commanding general of the U.S. Army Chemical and Biological Defense Command, at the Aberdeen Proving Ground in Maryland from August 1992 to August 1998; and deputy chief of staff for the Chemical and Biological Matters of the Army Material Command in Virginia during the same time. MG. Friel was also responsible for a $600 million annual budget for the Nuclear, Biological and Chemical Defense Command for six years and directed over 1,100 scientists and engineers. MG. Friel has also served as chairman of the board of the Nuclear Biological, and Chemical Defense Enterprise at the Edgewood Arsenal in Maryland and the U.S. Army Material Command, Acquisition and Procurement Enterprise. MG. Friel earned an M.B.A. from Northwest Missouri State University and a B.S. from the University of Nebraska. He is a graduate from the U.S. Army Chemical School, The Army Command and General Staff College, and The Industrial College of the Armed Forces. He was a director for Engineer Support Systems, Inc. from September 1998 until January 2006.

Gerald M. Olderman
Vice President, Research & Development and Commercialization

Dr. Olderman brings 35 years of heath-care experience, 31 years of technical management experience, and 25 years serving as the head of research and development activities for fortune 500 companies. Dr. Olderman has been vice president of research & development since 1997, and a member of the board of director since July 2000. Since November 1996, Dr. Olderman is the vice president and associate of R. F. Caffrey & Associates Inc., a management consultant to medical device companies and suppliers. Prior to joining R.F. Caffrey & Associates, Dr. Olderman served as director and head of research and development for C.R. Bard, Inc. (cardiopulmonary division), where he organized a new product development process in which 19 new medical devices were deployed. Dr. Olderman also served a vice president for domestic and international research and development for the Pharmaceutical Division of Baxter Healthcare Corp. and vice president for research and development for converters, a division of American Hospital Supply Corporation prior to its acquisition by Baxter Healthcare Corporation, where he led product development and made material changes that helped increase market share from 30% to 45% within a $750 million market. Dr. Olderman has also served as vice president for research and development and as director for Surgikos, Inc., a subsidiary of Johnson & Johnson Company. Dr. Olderman received a B.S. in Chemistry from Rensselaer Polytechnic Institute and also holds a M.S. in Physical Chemistry and a Ph.D. in Physical Chemistry from Seton Hall University.

Gregory S. S. Schultz
Vice President, Laboratory & Clinical Research

Dr. Schultz has served as our Vice President, Laboratory and Clinical Research since July 2000. From 1999 through 2001, Dr. Schultz served as the President of the Wound Healing Society, and has worked as a consultant for 12 major biotechnology companies. In 1989, he was appointed Professor of Obstetrics/Gynecology and Director of the Institute for Wound Research in the College of Medicine at the University of Florida at Gainesville, Florida. He has published over 200 research articles and book chapters that have been cited over 4,000 times. He has been continuously funded by major grants from the National Institutes of Health and supported by grants from the U.S. Army grant on treatment of burns with growth factors. Dr. Schultz earned a doctorate in biochemistry from Oklahoma State University and postdoctoral fellowship in cell biology at Yale University in Connecticut.